Small-Molecule Drugs in Pediatric Neuro-Oncology.

Area of Science:

• Pediatric Neuro-oncology
• Molecular Diagnostics
• Precision Medicine

Background:

• Molecular diagnostics advance precision medicine for pediatric central nervous system (CNS) tumors.
• Small-molecule drugs target specific genetic and epigenetic alterations in CNS tumors.
• This review focuses on emerging small-molecule agents in pediatric neuro-oncology.

Purpose of the Study:

• To provide an overview of small-molecule agents for pediatric CNS tumors.
• To highlight mechanisms of action, pharmacokinetics, efficacy, and tolerability.
• To identify limitations and future research needs for these therapies.

Main Methods:

• Review of small-molecule agents under investigation or in early clinical use.
• Focus on agents like ONC201, tazemetostat, vorasidenib, CDK inhibitors, selinexor, and aurora kinase A inhibitors.
• Analysis of preclinical and early-phase clinical data in pediatric populations.

Main Results:

• Several small-molecule agents show promise for pediatric CNS tumors.
• Early data indicate varying efficacy, pharmacokinetic profiles, and tolerability.
• Limitations include study heterogeneity, lack of large pediatric trials, and CNS drug delivery challenges.

Conclusions:

• Small-molecule drugs represent a promising therapeutic avenue in pediatric neuro-oncology.
• Robust prospective clinical trials are essential for clinical integration.
• Addressing challenges in study design and drug delivery is critical for advancing care.